Bullous pemphigoid (BP) is the most common autoimmune subepidermal blistering disease of the skin, which mainly affects elderly patients with frequent neurological comorbidities.
1 Bullous pemphigoid is associated with significant morbidity and an increased death rate that seems to differ throughout the world. In Europe, the 1-year death rate ranged from 0 to 52%,
2,3 whereas it ranged from 11% to 23% in the US
4,5 and from 0 to 42% in Asia.
6,7